Camptothecins

Camptothecin analogues and derivatives appear to exert their antitumour activity by binding to topoisomerase I and have shown significant activity against a broad range of tumours. In general, camptothecins are not substrates for either the multidrug-resistance P-glycoprotein or the multidrug-resistance-associated protein (MRP). Because of manageable toxicity and encouraging activity against solid tumours, camptothecins offer promise in the clinical management of human tumours. This review illustrates the proposed mechanism(s) of action of camptothecins and presents a concise overview of current camptothecin therapy, including irinotecan and topotecan, and novel analogues undergoing clinical trails, such as exatecan (DX-8951f), IDEC-132 (9-aminocamptothecin), rubitecan (9-nitrocamptothecin), lurtotecan (GI-147211C), and the recently developed homocamptothecins diflomotecan (BN-80915) and BN-80927.

[1]  Alfonso Mondragón,et al.  Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I , 1994, Nature.

[2]  L. Liu,et al.  Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Reinberg,et al.  DNA topoisomerase I is involved in both repression and activation of transcription , 1993, Nature.

[4]  N. Cozzarelli.  DNA gyrase and the supercoiling of DNA. , 1980, Science.

[5]  Y. Mao,et al.  p53 dependence of topoisomerase I recruitment in vivo. , 2000, Cancer research.

[6]  S. Arbuck,et al.  Clinical status and optimal use of topotecan. , 1997, Oncology.

[7]  H. Vosberg,et al.  Characterisation of size variants of type I DNA topoisomerase isolated from calf thymus. , 1984, European journal of biochemistry.

[8]  E. Di Mauro,et al.  Eukaryotic DNA topoisomerase I reaction is topology dependent. , 1988, Nucleic acids research.

[9]  D. Kessel,et al.  Effects of camptothecin on RNA synthesis in leukemia L1210 cells. , 1971, Biochimica et biophysica acta.

[10]  The Cascade Radical Annulation Approach to New Analogues of Camptothecins: Combinatorial Synthesis of Silatecans and Homosilatecans , 2000, Annals of the New York Academy of Sciences.

[11]  T. Shimazoe,et al.  Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude Mice , 1997, Japanese journal of cancer research : Gann.

[12]  J. Wang,et al.  Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Rothenberg.  The Current Status of Irinotecan (CPT‐11) in the United States , 1996, Annals of the New York Academy of Sciences.

[14]  P. Pantazis,et al.  Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. , 1993, Oncology research.

[15]  J. Verweij,et al.  Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[16]  K. Uoto,et al.  Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues. , 1994, Journal of medicinal chemistry.

[17]  G. Weiss,et al.  Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Wani,et al.  Antineoplastic agents from plants. , 1977, Annual review of pharmacology and toxicology.

[19]  L. Liu,et al.  DNA topoisomerases as anticancer drug targets. , 1990, Advances in pharmacology.

[20]  H. Pinedo,et al.  Camptothecins New Anticancer Agents , 1994 .

[21]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[22]  G. Rosner,et al.  Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Piette,et al.  Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. , 1996, Nucleic acids research.

[24]  A. Tolcher,et al.  DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Zelterman,et al.  Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Tsuruo,et al.  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[27]  R. Paridaens,et al.  Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  K. Uoto,et al.  A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo , 1995, Japanese journal of cancer research : Gann.

[29]  D. Toppmeyer,et al.  A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Baccanari,et al.  Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Y. Pommier,et al.  The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. , 2000, Journal of medicinal chemistry.

[32]  T. Lynch,et al.  Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  L. Moore,et al.  Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. , 1993, Journal of medicinal chemistry.

[34]  R. Pazdur,et al.  Colorectal cancer: chemotherapy treatment overview. , 2000, Oncology.

[35]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[36]  H. Ohmatsu,et al.  Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. , 1992, Journal of the National Cancer Institute.

[37]  C. Pacilio,et al.  Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  S. Penman,et al.  Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin. , 1972, Nature: New biology.

[39]  M. Wani,et al.  Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. , 1980, Journal of medicinal chemistry.

[40]  S. Shuman.  Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Kensuke Matsumoto,et al.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice , 2004, Cancer Chemotherapy and Pharmacology.

[42]  J. Besterman.  Topoisomerase I Inhibition by the Camptothecin Analog G1147211C , 1996 .

[43]  E. Vokes,et al.  Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer , 2000, Investigational New Drugs.

[44]  T. Taguchi,et al.  [Phase I clinical study of CPT-11. Research group of CPT-11]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[45]  C. Bailly,et al.  The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison , 2001, Anti-cancer drugs.

[46]  R. D. Anderson,et al.  Mutagenicity and carcinogenicity of topoisomerase-interactive agents , 1994 .

[47]  B. Giovanella,et al.  Modified Lactone/Carboxylate Salt Equilibria in Vivo by Liposomal Delivery of 9‐Nitro‐Camptothecin , 2000, Annals of the New York Academy of Sciences.

[48]  D. V. Von Hoff,et al.  Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Ajani,et al.  Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. , 2000, Oncology.

[50]  Y. Ohashi,et al.  Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. , 1994, British Journal of Cancer.

[51]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity , 1991 .

[52]  E. Kleinerman,et al.  9‐Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice , 2000, Annals of the New York Academy of Sciences.

[53]  W. Earnshaw,et al.  High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. , 1986, Science.

[54]  J. Wang,et al.  Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[55]  P. Brown,et al.  A sign inversion mechanism for enzymatic supercoiling of DNA. , 1979, Science.

[56]  D. Emerson,et al.  In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. , 1995, Cancer research.

[57]  L. Grochow,et al.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Eisenhauer,et al.  Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study , 1999, Leukemia.

[59]  S. Shuman.  DNA strand transfer reactions catalyzed by vaccinia topoisomerase I. , 1992, The Journal of biological chemistry.

[60]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[61]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[62]  J. Boehm,et al.  Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. , 1991, Journal of medicinal chemistry.

[63]  S. Culine,et al.  Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.

[64]  T. Taguchi,et al.  Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Chung-Cheng Liu,et al.  Type II DNA topoisomerases: Enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break , 1980, Cell.

[66]  T. Yoshimoto,et al.  CPT-11 converting enzyme from rat serum: purification and some properties. , 1991, Journal of pharmacobio-dynamics.

[67]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[68]  J. Wang,et al.  Supercoiling of the DNA template during transcription. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[69]  E. Pearlman,et al.  Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  C. Bailly,et al.  Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. , 1999, Biochemistry.

[71]  Y. Pommier,et al.  Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. , 1995, Cancer research.

[72]  J. Champoux.  DNA is linked to the rat liver DNA nicking-closing enzyme by a phosphodiester bond to tyrosine. , 1981, The Journal of biological chemistry.

[73]  A. Grollman,et al.  Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. , 1971, Molecular pharmacology.

[74]  P. de Souza,et al.  9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  K. Yamaguchi,et al.  Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. , 1991, Chemical & pharmaceutical bulletin.

[76]  S. Kaufmann.  Cell death induced by topoisomerase-targeted drugs: more questions than answers. , 1998, Biochimica et biophysica acta.

[77]  L. Liu,et al.  The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. , 1992, Cancer research.

[78]  J. Wang,et al.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[79]  W. Wilson,et al.  Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  M. Muller,et al.  Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair. , 1998, Cancer research.

[81]  J. Douillard.  Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. , 2000, Oncology.

[82]  D. Bigg,et al.  BN 80245: An E-Ring Modified Camptothecin with Potent Antiproliferative and Topoisomerase I Inhibitory Activities. , 1997 .

[83]  L. Liu,et al.  DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. , 1989, Cancer research.

[84]  M. Horwitz,et al.  Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. , 1971, Biochemical and biophysical research communications.

[85]  C. Verschraegen,et al.  A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. , 1999, Anti-cancer drugs.

[86]  Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. , 1998, Journal of medicinal chemistry.

[87]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[88]  P. Caron,et al.  The role of DNA topoisomerases in recombination and genome stability: A double-edged sword? , 1990, Cell.

[89]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[90]  P. Cheverton,et al.  DX‐8951f: Summary of Phase I Clinical Trials , 2000, Annals of the New York Academy of Sciences.

[91]  R. Ohno,et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  G. Weiss,et al.  A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  J. Petros,et al.  Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. , 1998, The Journal of urology.

[94]  D. S. Pilch,et al.  A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin. , 2001, Biochemistry.

[95]  R. Sternglanz,et al.  Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I. , 1989, The Journal of biological chemistry.

[96]  L. Liu,et al.  Processing of topoisomerase I cleavable complexes into DNA damage by transcription. , 1997, Nucleic acids research.

[97]  FDA approves irinotecan as first-line therapy for colorectal cancer. , 2000, Oncology.

[98]  P. Kasprzyk,et al.  The Dual Topoisomerase Inhibitor, BN 80927, Is Highly Potent against Cell Proliferation and Tumor Growth , 2000, Annals of the New York Academy of Sciences.

[99]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[100]  J. Wang,et al.  Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Y. Pommier,et al.  Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. , 2000, Cancer research.

[102]  N. Saijo.  Clinical Trials of Irinotecan Hydrochloride (CPT, Campto Injection, Topotecin Injection) in Japan a , 1996, Annals of the New York Academy of Sciences.

[103]  P. Pantazis,et al.  Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non‐tumorigenic and tumorigenic cells in vitro , 1993, International journal of cancer.

[104]  M. Fukuoka,et al.  Irinotecan in small-cell lung cancer--Japanese trials. , 2000, Oncology.

[105]  G. Rosner,et al.  Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  H. Kantarjian,et al.  Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. , 1998, Leukemia & lymphoma.

[107]  John T. Lis,et al.  Topoisomerase I interacts with transcribed regions in Drosophila cells , 1986, Cell.

[108]  K. Kohn,et al.  Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[109]  N. Berger,et al.  International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. , 1994, Mutation research.

[110]  N. Osheroff.  Biochemical basis for the interactions of type I and type II topoisomerases with DNA. , 1989, Pharmacology & therapeutics.

[111]  K. Kohn,et al.  Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin. , 1990, Journal of medicinal chemistry.

[112]  M. Wani,et al.  Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. , 1986, Journal of medicinal chemistry.

[113]  Y. Cheng,et al.  Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. , 1995, Molecular pharmacology.

[114]  R. Hertzberg,et al.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. , 1989, Journal of medicinal chemistry.

[115]  D. Kessel,et al.  Camptothecin effects on DNA synthesis in murine leukemia cells. , 1972, Biochimica et biophysica acta.

[116]  C. Rogler,et al.  Topoisomerase I-mediated integration of hepadnavirus DNA in vitro , 1991, Journal of virology.

[117]  J. Armand,et al.  A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  M. Potměšil,et al.  Camptothecins: from bench research to hospital wards. , 1994, Cancer research.

[119]  R. Kiss,et al.  Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. , 1999, Cancer research.

[120]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[121]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[122]  L. Liu,et al.  Topoisomerase-targeting antitumor drugs. , 1989, Biochimica et biophysica acta.

[123]  H. Vosberg.  DNA topoisomerases: enzymes that control DNA conformation. , 1985, Current topics in microbiology and immunology.

[124]  L. Saltz.  Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. , 2000, Oncology.

[125]  J. Champoux.  Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3'-terminus of the nicked DNA. , 1978, Journal of molecular biology.

[126]  D. Kufe,et al.  Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. , 1991, Cancer research.

[127]  A. Tohgo,et al.  Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice , 1998, Cancer Chemotherapy and Pharmacology.

[128]  G. Weiss,et al.  A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days , 1992, Anti-cancer drugs.

[129]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[130]  Leroy F. Liu,et al.  Transcription generates positively and negatively supercoiled domains in the template , 1988, Cell.

[131]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[132]  W. Earnshaw,et al.  cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[133]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[134]  J. Alsner,et al.  Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. , 1992, Journal of molecular biology.

[135]  M. Gellert,et al.  DNA topoisomerases. , 1981, Annual review of biochemistry.

[136]  P. Kasprzyk,et al.  Homocamptothecins: E‐Ring Modified CPT Analogues , 2000, Annals of the New York Academy of Sciences.

[137]  L. Liu,et al.  Roles of DNA topoisomerases in transcription. , 1994, Advances in pharmacology.

[138]  S. Arbuck,et al.  Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  M. Rothenberg.  Topoisomerase I inhibitors: review and update. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[141]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[142]  L. Keus,et al.  Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. , 2006, Annals of the New York Academy of Sciences.

[143]  M. Yakushiji,et al.  [An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers]. , 1991, Gan to kagaku ryoho. Cancer & chemotherapy.

[144]  M. Fukuoka,et al.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[145]  M. Potměšil,et al.  Preclinical and clinical development of camptothecins. , 1994, Advances in pharmacology.

[146]  J. Verweij,et al.  Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. , 1996, British Journal of Cancer.

[147]  L. Liu,et al.  Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[148]  S. Shuman,et al.  Recombination mediated by vaccinia virus DNA topoisomerase I in Escherichia coli is sequence specific. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[149]  T. Harris,et al.  Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation. , 1997, Biochemistry.

[150]  E. Estey,et al.  Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study , 2004, Investigational New Drugs.

[151]  P. Pantazis,et al.  Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. , 1992, Cancer research.

[152]  C. Takimoto,et al.  The Clinical Development of 9‐Aminocamptothecin , 2000, Annals of the New York Academy of Sciences.

[153]  J N Weinstein,et al.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. , 1998, Journal of medicinal chemistry.

[154]  G. Manikumar,et al.  Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. , 1987, Journal of medicinal chemistry.

[155]  M. Wani,et al.  Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. , 1986, Journal of medicinal chemistry.

[156]  M. Wani,et al.  Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5'(RS)-1,5-dioxo-5'-ethyl-5'-hydroxy-2'H,5'H,6'H-6'-oxopyrano[3' ,4'- f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. , 1987, Journal of medicinal chemistry.

[157]  L. Liu,et al.  DNA topoisomerases--enzymes that catalyse the breaking and rejoining of DNA. , 1983, CRC critical reviews in biochemistry.

[158]  J A Gottlieb,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972, Cancer chemotherapy reports.

[159]  M. Fukuoka,et al.  Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  P. Pantazis,et al.  The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. , 1995, Leukemia research.

[161]  K. Kohn,et al.  Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.

[162]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[163]  A. Guarino,et al.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.

[164]  D. Crothers,et al.  Structural modifications of camptothecin and effects on topoisomerase I inhibition. , 1992, Journal of medicinal chemistry.